TrialEuropean urology oncology2020

Temsirolimus versus Pazopanib (TemPa) in Patients with Advanced Clear-cell Renal Cell Carcinoma and Poor-risk Features: A Randomized Phase II Trial.

Nizar M Tannir et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.